Beta-1,6-N-acetylglucosamine-branched N-glycans (β1,6-GlcNAc N-glycans)

Beta-1,6-N-acetylglucosamine (β1,6-GlcNAc)-branched N-glycans are complex carbohydrate structures primarily synthesized by the enzyme N-acetylglucosaminyltransferase V (MGAT5) (Dennis et al., 1987). These glycans are a hallmark of malignant transformation, where their increased density on cell surface receptors like EGFR and integrins promotes cell motility, epithelial-mesenchymal transition (EMT), and metastasis (Pinho & Reis, 2015). The Leukoagglutinating Phytohemagglutinin (L-PHA) lectin, derived from Phaseolus vulgaris, possesses a high affinity for these specific branched structures, serving as a critical tool for both detection and therapeutic targeting (Lau & Dennis, 2008). In modern oncology, the L-PHA lectin domain is being engineered into chimeric antigen receptors (CARs) to create Lecti-CAR T-cells capable of recognizing the aberrant glycosylation patterns of tumor cells (He et al., 2021). This approach allows for the targeting of a broad range of solid tumors that share this common post-translational modification, potentially overcoming the limitations of protein-specific antigens. However, therapeutic development must account for the presence of these glycans on certain healthy tissues, such as activated lymphocytes, which poses a risk for on-target off-tumor toxicity (Pinho & Reis, 2015).

Other names

MGAT5-modified N-glycansL-PHA-reactive glycansBeta-1,6-branched N-glycansTri- and tetra-antennary N-glycansβ1,6-branched oligosaccharides

Targeted binding of the L-PHA lectin domain to β1,6-GlcNAc-branched N-glycans on the cell surface to facilitate immune-mediated cell killing or drug delivery.